Global recruitment of Group Lead (POC team)

1. Job Summary

As the innovation and drug discovery hub of SINOVAC, the United Research Institute of SINOVAC (URIS) is committed to “uniting the power of global science and promoting global health”. Established in 2023, URIS focuses on unmet medical needs, integrating cutting-edge research and significant findings to develop first-class innovation in vaccines, antibodies, and cell gene therapy, accelerating the market launch of high-quality products. URIS is recruiting a Group Lead to lead its POC project groups. We invite outstanding scientists to join URIS to carry out drug discovery and early concept validation for infectious diseases, chronic diseases, and other drugs and vaccines. We hope to work with scientific leaders in basic science and translational research to develop the next generation of innovative drugs.

2. Roles and Responsibilities

1. Lead a research team of 3-5 members, develop and execute project plans, and ensure timely completion of projects.
2. Independently design and conduct early-stage research projects on vaccines and biopharmaceuticals, ensuring scientific rigor and feasibility. Develop detailed experimental plans and supervise their implementation.
3. Track project progress, monitor project risks, pay attention to industry trends and cutting-edge technologies, and continuously optimize project plans and strategies.
4. Effective communication and teamwork within the group, project teams, and intra and inter-departmental functions, as well as with external stakeholders.
5. Write project research reports, technical documents, and patent applications to protect project results and intellectual property rights.
6. Assist in subsequent pharmaceutical and clinical development and provide technical support and scientific advice.

3. Qualification and Requirements

1. Ph.D degree in biology, immunology, pharmacy, chemistry, or other related fields, with a solid theoretical foundation and experimental skills.
2. Experience independently conducting research projects, with more than 3 years of research experience in vaccines and biopharmaceuticals.
3. Familiar with the research and development process and relevant regulation for vaccines and biopharmaceuticals, with a deep understanding of product design and concept validation.
4. Team management and leadership skills, able to drive the efficient completion of research and development tasks.
5. Good communication skills and teamwork, able to effectively communicate with different departments to ensure the project runs smoothly.
6. Possess innovation and problem-solving abilities, able to propose solutions during the research and development process.
7. Strong English listening, speaking, reading, and writing skills; able to read English literature and write English research reports.
8. Ability to work under pressure and shoulder responsibility.

About SINOVAC

Sinovac Biotech Ltd. (SINOVAC) is a Chinese biopharmaceutical company that focuses on the R&D, manufacturing, and commercialization of vaccines and antibodies. SINOVAC also produces other preventive and therapeutic products that protect against human infectious diseases.

SINOVAC is dedicated to addressing major challenges in disease prevention and treatment through cutting-edge technology. We focus on unmet medical needs regarding infectious disease and other significant therapeutic areas. All our work integrates cutting-edge research and major findings from across the world, concentrating strengths to develop first-in-class biopharmaceuticals such as vaccines, antibodies, and fusion proteins, ensuring high-quality products reach the market swiftly. Our high R&D standards are backed by innovation-driven platforms such as the United Research Institute of SINOVAC (URIS) for drug discovery and our product-oriented CMC platform. We also run clinical demand support platforms such as our Analysis Center and Animal Center for Drug Evaluation. Our world-class facilities mean we have a mature system for developing preventive and therapeutic products, with multiple types of technologies including our own core technologies. Our multidisciplinary research team, covering fields such as pharmacy, biology, medicine, and chemistry, are at the forefront of global research and innovation.

Going forward, SINOVAC will promote both the research and industrialization of biopharmaceuticals. While continuing to develop its vaccine industry, we will also expand our markets in therapeutic monoclonal antibodies, gene therapy, and cell therapy. Through independent R&D, collaboration, and external investment, we will accelerate the industrialization of high-quality biopharmaceuticals to fulfil global disease prevention and control, improving global health and well-being.

Since being founded in 2001, our mission has been to “supply vaccines to eliminate human diseases”. SINOVAC has developed a comprehensive portfolio including vaccines against common infectious diseases like hepatitis virus, seasonal influenza, pneumococcal disease, poliomyelitis, varicella, and mumps, as well as emerging ones, such as COVID-19, enterovirus71 (EV71) related Hand-Foot-Mouth disease (HFMD), H5N1 influenza (avian flu), H1N1 influenza (swine flu) and SARS.

Thanks to its comprehensive quality management, SINOVAC has four vaccines approved by the World Health Organization (WHO). Its hepatitis A vaccine Healive®, Sabin-strain inactivated poliomyelitis vaccine (sIPV), and varicella vaccine were granted WHO prequalification (“PQ”); and its COVID-19 vaccine CoronaVac® was validated by the WHO under the Emergency Use Listing (“EUL”) Procedure.